Reference

Isolation and structural elucidation of urinary metabolites of ciprofloxacin

Isolation and structural elucidation of urinary metabolites of ciprofloxacin. Gau, W.; Kurz, J.; Petersen, U.; Ploschke, H. J.; Wuensche, C. (Pharma Div., Bayer A.Some commonly used reagents like 105589-00-2 and 93107-30-3 are used in this experiment.-G., Wuppertal D-5600/1, Fed. Rep. Ger.). Arzneim.-Forsch., 36(10), 1545-9 (English) 1986. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Section cross-reference(s): 28 After oral administration of Ciprobay (ciprofloxacin) (I) [85721-33-1], 4 metabolites were isolated from human urine by Craig countercurrent distribution and semipreparative HPLC. The mol. structures of the metabolites were elucidated by NMR and mass spectrometry and confirmed by comparing their spectra with those of authentic synthetic ref. compds. .

Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia

Comparative activities of ciprofloxacin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Pennington, J.; Kemmerich, B.; Schiff, J.; Small, G. (Dep. Med., Brigham and Women's Hosp., Boston, MA, USA). Recent Adv. Chemother., Proc. Int. Congr. Chemother., 14th, Issue Antimicrobial Sect. 2, 1875-6. Edited by: Ishigami, Joji. Univ.Several substances with their cas registry numbers 37091-66-0 and 32986-56-4 may be metioned in this study. Tokyo Press: Tokyo, Japan. (English) 1985. CODEN: 55GNAX. DOCUMENT TYPE: Conference CA Section: 1 (Pharmacology) Section cross-reference(s): 10 The therapeutic efficacy of ciprofloxacin (CIP) [85721-33-1] was compared with those of ticarcillin (TLC) [34787-01-4] and tobramycin (TOB) [32986-56-4] in guinea pigs with exptl. P. aeruginosa pneumonia. Survival and intrapulmonary killing of P. aeruginosa among CIP-treated animals was superior to that in TIC-treated and equal to that in TOB-treated animals. Therapy with CIP alone was equiv. in efficacy to that with combinations of CIP with TOB, azlocillin [37091-66-0], or ceftazidime [72558-82-8]. In a more chronic P. aeruginosa pneumonia model, CIP treatment also resulted in superior intrapulmonary killing of bacteria as compared to TOB and TIC. Thus, CIP may be useful in the treatment of acute and more chronic forms of pulmonary infection caused by P. aeruginosa. .